Pfizer News & Analysis
2 articles
Market Mood
Innovent (HK:1801) Shares Rise 10% After $10.5 Billion Pfizer Deal
Shares of Innovent Biologics (HK:1801) increased by 10% following a deal with Pfizer valued up to $10.5 billion for the development of oncology medicines. The agreement includes an upfront payment of $650 million and up to $9.85 billion in milestone payments. Innovent will collaborate on four global programs, co-commercializing in the U.S. and Europe while retaining rights in Greater China. These developments come as partnerships between biotech and pharmaceutical firms are critical in addressing oncology disease concerns globally.
Read More
Pfizer Seeks FDA Approval for Lyme Disease Vaccine with 70% Efficacy
Pfizer reported that its Lyme disease vaccine candidate demonstrated 70% efficacy in clinical trials. Despite this achievement, the vaccine missed a key statistical goal, which has raised concerns about its potential market impact. The company, along with its French partner Valneva, plans to pursue FDA approval even though low case numbers of Lyme disease contributed to the trial's challenges. This decision could signal significant developments in the vaccine market and impact future investor sentiment.
Read More